Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,494 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

NCT00646867
View directory record Official record
Conditions
Contact Dermatitis
Interventions
Tetrix, Placebo
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 20, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

NCT00198081
View directory record Official record
Conditions
Pancreas Neoplasms
Interventions
COX-2 Inhibitor 6-8 weeks prior to surgery, COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 20, 2026, 9:23 AM EDT
Not yet recruiting Not applicable Interventional

NeuroCuple to Mitigate Post-Wisdom Teeth Extraction Opioid Risks

NCT07461506
View directory record Official record
Conditions
Wisdom Teeth, Wisdom Teeth Extraction or Jaw Implant
Interventions
NEUROCUPLE™ Patch, Sham Patch
Device
Lead sponsor
nCap Medical
Industry
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Apical Negative Pressure Irrigation System at Cleaning Lateral Canals and Reduction of Periapical Lesions After Endodontic Therapy

NCT03384004
View directory record Official record
Conditions
Root Canal Infection
Interventions
Irrigation Technique 1, Irrigation Technique 2
Device
Lead sponsor
KaVo Kerr
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Niles, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Results available

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

NCT04462471
View directory record Official record
Conditions
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
Interventions
I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study

NCT05683821
View directory record Official record
Conditions
Quitting Smoking, Smoking Cessation, Smoking, Cigarette
Interventions
Text message smoking treatment, Nicotine replacement therapy sampling, Wisconsin Tobacco QuitLine Referral, Referral to Primary Care Provider, BREATHE 2 Cessation Study, Additional modalities to learn about and request treatment
Behavioral · Drug · Combination Product
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12,376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Active, not recruiting No phase listed Observational

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

NCT04275557
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Cyst
Interventions
Blood Sample collection, Tissue sample collection, Data collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Lakewood Rch, Florida • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Terminated Not applicable Interventional

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

NCT05513027
View directory record Official record
Conditions
Cancer
Interventions
Augmented Whole-body Scanning via Magnifying PET, PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

NCT00903461
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
EGFR Antisense DNA
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02684253
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 20, 2026, 9:23 AM EDT
Completed No phase listed Observational Results available

The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)

NCT01943903
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Redwood City, California • Stanford, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 20, 2026, 9:23 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions

NCT02802553
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Smart Goggle, Cardio-Green, SPY Elite Imaging system, Quest near-infrared (NIR) Imaging system, PDE Imaging system, Gamma probe, Blue Dyes
Device · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

NCT05672901
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
StrataMGT, Estrace 0.01% Vaginal Cream
Device · Drug
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Healthy Brain Development: Wellness for 2 Study

NCT05052281
View directory record Official record
Conditions
Prenatal Stress
Interventions
Mothers and Babies (MB) Course, Just in Time Intervention (JITI) Content, Biostamp nPoint Device
Behavioral · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

NCT03499795
View directory record Official record
Conditions
Anal Neoplasm
Interventions
VGX-3100, CELLECTRA™ 5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Smoking Cessation After Hospitalization for a Cardiopulmonary Illness

NCT01791803
View directory record Official record
Conditions
Smoking Cessation
Interventions
hypnotherapy, Nicotine
Behavioral · Drug
Lead sponsor
North Shore Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

NCT06851754
View directory record Official record
Conditions
Premature Ovarian Insufficiency
Interventions
Progesterone, Estrogen Patch
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
11 Years to 19 Years · Female only
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466
View directory record Official record
Conditions
Common Warts
Interventions
Nanopulse System
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

MAST Trial: Multi-modal Analgesic Strategies in Trauma

NCT03472469
View directory record Official record
Conditions
Nonspecific Pain Post Traumatic Injury
Interventions
Acetaminophen IV/PO, Acetaminophen PO, Ketorolac, Celebrex, Naproxen, Tramadol, Pregabalin, Gabapentin, Lidocaine, Opioids, Regional anesthesia
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
View directory record Official record
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Nicotine transdermal patch, PET Scan with [18F] VAT
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 20, 2026, 9:23 AM EDT